Filing Details
- Accession Number:
- 0001209191-15-025790
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-03-12 19:24:54
- Reporting Period:
- 2015-03-12
- Filing Date:
- 2015-03-12
- Accepted Time:
- 2015-03-12 19:24:54
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 949699 | Pharmacyclics Inc | PCYC | Pharmaceutical Preparations (2834) | 943148201 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1555167 | Heow Tan | C/O Pharmacyclics, Inc. 995 East Arques Avenue Sunnyvale CA 94085 | Chief Quality&Tech Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-03-12 | 1,000 | $27.05 | 5,070 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-03-12 | 1,000 | $254.51 | 4,070 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2015-03-12 | 1,000 | $0.00 | 1,000 | $27.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 75,304 | 2012-05-07 | 2022-05-07 | No | 4 | M | Direct |
Footnotes
- The option shares vest 25% on each of April 11, 2013, April 11, 2014, April 11, 2015 and April 11, 2016, subject to satisfaction of certain performance criteria with respect to each vesting period. Such performance criteria is to be determined and approved by the Compensation Committee.
Billionaire Hedge Funds
